ClinicalTrials,

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Conditions:   Non-small Cell Lung Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Esophageal SCC;   Gastrointestinal Stromal Tumors;   Colorectal CancerInterventions:   Drug: TNO155;   Drug: Spartalizumab;   Drug: RibociclibSponsor:   Novartis PharmaceuticalsNot yet recruiting

ClinicalTrials

15:55